Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

PolyNovo (PNV AU): FY23 Result- Sales Momentum Accelerates; Net Loss Widens on Higher Opex

PolyNovo (PNV AU): 1H23 Result- Growth Trajectory Continues; Fund Raising Strengthens Balance Sheet

PolyNovo Ltd (PNV AU): Shares Are Rallying Fueled by Strong US Sales and New Product Approval

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/polynovo-ltd" target="_blank" data-smartkarma-citation="entities:12208:1" rel="noopener">PolyNovo Ltd (PNV AU)</a> reported 29% YoY growth in FY25 revenue to A$119M, driven by 29% YoY growth in U.S. sales to A$88M. RoW sales grew 30% YoY to AS$30M.</li>
<li>PolyNovo expects continued sales growth as multiple products received relevant regulatory clearance. Leveraging on proven track record in full thickness burn procedures, PolyNovo is driving adoption in additional surgical areas.</li>
<li>Strong FY25 result enhances conviction on the growth prospects. Broader rollout of NovoSorb MTX across multiple regions and increasing demand from plastic and reconstructive procedures are expected drive growth.</li>
</ul>



PolyNovo Ltd (PNV AU) reported 29% YoY growth in FY25 revenue to A$119M, driven by 29% YoY growth in U.S. sales to A$88M. RoW sales grew 30% YoY to AS$30M.
PolyNovo expects continued sales growth as multiple products received relevant regulatory clearance. Leveraging on proven track record in full thickness burn procedures, PolyNovo is driving adoption in additional surgical areas.
Strong FY25 result enhances conviction on the growth prospects. Broader rollout of NovoSorb MTX across multiple regions and increasing demand from plastic and reconstructive procedures are expected drive growth.


PolyNovo (PNV AU): Solid FY25 Performance; Label and Geography Expansion to Accelerate Growth